Adult T-Cell Leukemia/Lymphoma

Diseases /

Adult T-Cell Leukemia/Lymphoma

Back to Diseases List

Associated Genetic Biomarkers

CD2 Expression
CD3 Expression
CD3D Expression
CD3E Expression
CD3G Expression
CD4 Expression
CD5 Expression
CD7 Expression
EBV Positive
HTLV1 Positive
TNFRSF8 Deficient Expression
TNFRSF8 Expression
TNFRSF8 Overexpression
p40 Expression Positive

Overview

NCI Definition: A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1). Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. [1]

Clinical Trials

View Clinical Trials for Adult T-Cell Leukemia/Lymphoma

There are 25 clinical trials for adult T-cell leukemia/lymphoma, of which 18 are open and 7 are completed or closed. Of the trials that contain adult T-cell leukemia/lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 11 are phase 1 (8 open), 11 are phase 2 (9 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open).

TNFRSF8, CD4, and CD7 are the most frequent gene inclusion criteria for adult T-cell leukemia/lymphoma clinical trials [3].

Trials Investigating Adult T-Cell Leukemia/Lymphoma by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and brentuximab vedotin are the most common interventions in adult T-cell leukemia/lymphoma clinical trials.

Drugs Being Investigated in Adult T-Cell Leukemia/Lymphoma Trials by Recruiting Status

Significant Genes in Adult T-Cell Leukemia/Lymphoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain ABL1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain AFF1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain BCR status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [3].

CBFB +

CBFB is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 4 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 4 are closed. Of the trials that contain FLT3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2A status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

MYH11 +

MYH11 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 +

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

Disease Details

Synonyms

Adult T-Cell Lymphoma/Leukemia, HTLV-I Associated Adult T-Cell Leukemia/Lymphoma, HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia, ATLL, Adult T Cell Lymphoma/Leukemia

Parent(s)

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Children

Smoldering Adult T-Cell Leukemia/Lymphoma and Lymphomatous Adult T-Cell Leukemia/Lymphoma

OncoTree Name

Adult T-Cell Leukemia/Lymphoma

OncoTree Code

ATLL

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Adult T-Cell Leukemia/Lymphoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Adult T-Cell Leukemia/Lymphoma

Disease Details

References

About

Molecular Medicine

Content Types